Cited by 147Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins

Friday, Bret B., Yu, Chunrong, Dy, Grace K., Smith, Paul D., Wang, Liang, Thibodeau, Stephen N., Adjei, Alex A.·2008·Cancer Research

DOI 10.1158/0008-5472.can-08-1430

Open this paper in CoChat — free account

Abstract

AZD6244 (ARRY 142886) is a potent and selective mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor currently in early clinical trials. We examined the activity of AZD6244 in a panel of non–small cell lung cancer and a panel of cell lines representing many cancer types using in vitro growth assays. AZD6244 induced G0-G1 cell cycle arrest in sensitive cell lines that primarily included cells containing the BRAF V600E mutation. In these cells, G0-G1 arrest is accompanied by the up-regulation of the cell cycle inhibitors p21WAF1 and p27Kip1 and down-regulation of cyclin D1. In the majority of cell lines tested, including those with K-ras or non-V600E BRAF mutations, AZD6244 induced the accumulation of phospho-MEK, an effect not observed in the most sensitive BRAF V600E-containing cells. Accumulation of phospho-MEK in non–V600E-containing cell lines is due to abrogation of negative feedback pathways. BRAF V600E disrupts negative feedback signaling, which results in enhanced baseline phospho-MEK expression. Exogenous expression of BRAF V600E disrupts feedback inhibition but does not sensitize cells to AZD6244. Specific suppression of endogenous BRAF V600E does not confer resistance to AZD6244 but enhances sensitivity to AZD6244. Thus, our findings show that BRAF V600E marks cells with an in vitro requirement for MAPK signaling to support proliferation. These cells are exquisitely sensitive to AZD6244 (IC50, <100 nmol/L), have high baseline levels of phospho-MEK, and lack feedback inhibition between ERK and Raf. These data suggest an approach to identifying cells that may be sensitive to AZD6244 and other MEK inhibitors. [Cancer Res 2008;68(15):6145–53]

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-1430

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081240 · Cited by 109
Retracted
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,293
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A. M., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A. J., Przybranowski, S. A., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 972
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
Regulation of Raf-1 by direct feedback phosphorylation.
Dougherty, M., Müller, J., Ritt, D. A., Zhou, M., Zhou, X.-Z., Copeland, T., Conrads, T., Veenstra, T., Lu, K., & Morrison, D. (2005) · Molecules and Cells · doi:10.1016/j.molcel.2004.11.055 · Cited by 663
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
Ohren, J. F., Chen, H., Pavlovsky, A. G., Whitehead, C. E., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C. A., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 635

Show all 44 references

Research works printed but not linked: 2

Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAFV599E in human melanoma abrogates transformation. Cancer Res 2003; 63: 5198–202.
Yeh T, Wallace E, Lyssikatos J, Winkler J. ARRY-142886, a potent and selective MEK inhibitor. II. Potency against cellular MEK leads to inhibition of cellular proliferation and induction of apoptosis in cell lines with mutant Ras or B-Raf. Proc Am Assoc Cancer Res 2004; 45: 3889.

Sorted by citations

RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Self-citation
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Dual‐specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling
Caunt, C. J., & Keyse, S. M. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08716.x · Cited by 535
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
PTEN: Multiple Functions in Human Malignant Tumors
Milella, M., Falcone, I., Conciatori, F., Incani, U. C., Curatolo, A. D., Inzerilli, N., Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00024 · Cited by 484
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., Halilovic, E., Persaud, Y., Xing, F., Viale, A. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008990107 · Cited by 446
The clinical development of MEK inhibitors
Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 410
Self-citation
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K. W., Price, S., Heald, R. A., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 317
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Faber, A. C., Li, D., Song, Y., Liang, M.-C., Yeap, B. Y., Bronson, R. T., Lifshits, E., Chen, Z., Maira, S.-M., García-Echeverría, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 319
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J. A., Larkin, J., Hersey, P., Middleton, M. R., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1491 · Cited by 276
Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032
Søndergaard, J. N., Nazarian, R., Wang, Q., Guo, D., Hsueh, T., Mok, S., Sazegar, H., MacConaill, L. E., Barretina, J., Kehoe, S. M., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-39 · Cited by 232
Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 211
Self-citation
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
Chen, X., Wu, Q., Tan, L., PORTER, D. A., Jager, M. J., Emery, C., & Bastian, B. C. (2013) · Oncogene · doi:10.1038/onc.2013.418 · Cited by 215
Strong negative feedback from Erk to Raf confers robustness to MAPK signalling
Fritsche‐Guenther, R., Witzel, F., Sieber, A., Herr, R., Schmidt, N., Braun, S. L., Brummer, T., Sers, C., & Blüthgen, N. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.27 · Cited by 200
Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
Stegmeier, F. P., Warmuth, M., Sellers, W. R., & Dorsch, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.297 · Cited by 196
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response
Pratilas, C. A., & Solit, D. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3064 · Cited by 183
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Matei, D. E., Sill, M. W., Lankes, H. A., DeGeest, K., Bristow, R. E., Mutch, D. G., Yamada, S. D., Cohn, D. E., Calvert, V. S., Farley, J. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7856 · Cited by 175
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 166
Network quantification of EGFR signaling unveils potential for targeted combination therapy
Klinger, B., Sieber, A., Fritsche‐Guenther, R., Witzel, F., Berry, L., Schumacher, D., Yan, Y., Durek, P., Merchant, M. A., Schäfer, R., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.29 · Cited by 155
Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
Meng, J., Dai, B., Fang, B., Bekele, B. N., Bornmann, W. G., Sun, D., Peng, Z., Herbst, R. S., Papadimitrakopoulou, V. A., Minna, J. D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014124 · Cited by 146
BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications
Tang, K., & Lee, C. (2010) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(10)70025-3 · Cited by 141
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
Wu, P., & Park, J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.023 · Cited by 144
Targeting the RAS oncogene
Takashima, A., & Faller, D. V. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.764990 · Cited by 140
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
Knauf, J. A., & Fagin, J. A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.013 · Cited by 131
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Nakamura, A., Arita, T., Tsuchiya, S., Donelan, J., Chouitar, J., Carideo, E. G., Galvin, K. M., Okaniwa, M., Ishikawa, T., & Yoshida, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1825 · Cited by 124
Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding
Agyeman, A., Jha, B. K., Mazumdar, T., & Houghton, J. A. (2014) · Oncotarget · doi:10.18632/oncotarget.2046 · Cited by 126
Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions
Batus, M., Waheed, S., Ruby, C. E., Petersen, L. F., Bines, S. D., & Kaufman, H. L. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0025-9 · Cited by 117
MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
Jiang, C. C., Lai, F., Thorne, R. F., Yang, F., Liu, H., Hersey, P., & Zhang, X. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2225 · Cited by 122
Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations
Ciuffreda, L., Bufalo, D. D., Desideri, M., Sanza, C. D., Stoppacciaro, A., Ricciardi, M. R., Chiaretti, S., Tavolaro, S., Benassi, B., Bellacosa, A., et al. (2009) · Neoplasia · doi:10.1593/neo.09398 · Cited by 111
Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
Ambrosini, G., Pratilas, C. A., Qin, L., Tadi, M., Surriga, O., Carvajal, R. D., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3086 · Cited by 110
Efficient synthesis of phycocyanobilin in mammalian cells for optogenetic control of cell signaling
Uda, Y., Goto, Y., Oda, S., Kohchi, T., Matsuda, M., & Aoki, K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707190114 · Cited by 109
Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling
Kidger, A. M., Rushworth, L. K., Stellzig, J., Davidson, J., Bryant, C., Bayley, C., Caddye, E., Rogers, T., Keyse, S. M., & Caunt, C. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614684114 · Cited by 100
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
Gazdar, A. F. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9201-z · Cited by 99
Targeting drivers of melanoma with synthetic small molecules and phytochemicals
Strickland, L. R., Pal, H. C., Elmets, C. A., & Afaq, F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.016 · Cited by 84
Feedback regulation in cell signalling: Lessons for cancer therapeutics
Nguyen, L. K., & Kholodenko, B. Ν. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.024 · Cited by 76
Novel Designs and End Points for Phase II Clinical Trials
Adjei, A. A., Christian, M. C., & Ivy, P. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2035 · Cited by 76
Self-citation
Multiplexed Fluorescence Imaging of ERK and Akt Activities and Cell-cycle Progression
Maryu, G., Matsuda, M., & Aoki, K. (2016) · Cell Structure and Function · doi:10.1247/csf.16007 · Cited by 76
NFAT5-mediated expression of S100A4 contributes to proliferation and migration of renal carcinoma cells
Küper, C. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00293 · Cited by 75
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
Annunziata, C. M., Hernandez, L. F., Davis, R. E., Zingone, A., Lamy, L., Lam, L. T., Hurt, E. M., Shaffer, A. L., Kuehl, W. M., & Staudt, L. M. (2010) · Blood · doi:10.1182/blood-2010-04-278788 · Cited by 75
Inducible Pluripotent Stem Cell–Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1 -Associated Noonan Syndrome
Jaffré, F., Miller, C. L., Schänzer, A., Evans, T., Roberts, A. E., Hahn, A., & Kontaridis, M. I. (2019) · Circulation · doi:10.1161/circulationaha.118.037227 · Cited by 73
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Yoon, Y., Kim, H., Han, S., Hur, H.-S., Oh, D. Y., Im, S., Bang, Y., & Kim, T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0300 · Cited by 73
Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells
Muralidharan-Chari, V., Kohan, H. G., Asimakopoulos, A. G., Sudha, T., Sell, S., Kannan, K., Boroujerdi, M., Davis, P. J., & Mousa, S. A. (2016) · Oncotarget · doi:10.18632/oncotarget.10395 · Cited by 71
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Berlak, M., Tucker, E. R., Dorel, M., Winkler, A., McGearey, A., Rodríguez-Fos, E., Costa, B. M. D., Barker, K. T., Fyle, E., Calton, E. A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01583-z · Cited by 65
An immediate–late gene expression module decodes ERK signal duration
Uhlitz, F., Sieber, A., Wyler, E., Fritsche‐Guenther, R., Meisig, J., Landthaler, M., Klinger, B., & Blüthgen, N. (2017) · Molecular Systems Biology · doi:10.15252/msb.20177554 · Cited by 60
Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines
Garon, E. B., Finn, R. S., Hosmer, W., Dering, J., Ginther, C., Adhami, S., Kamranpour, N., Pitts, S. L., Desai, A. J., Elashoff, D. A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0037 · Cited by 63
Self-citation
Emerging MEK inhibitors
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S. M., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., et al. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903282760 · Cited by 63
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
Meng, J., Peng, H., Dai, B., Guo, W., Wang, L., Ji, L., Minna, J. D., Chresta, C. M., Smith, P. D., Fang, B., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9844 · Cited by 61
Self-citation
Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
Yoshida, T., Kakegawa, J., Yamaguchi, T., Hantani, Y., Okajima, N., Sakai, T., Watanabe, Y., & Nakamura, M. (2012) · Oncotarget · doi:10.18632/oncotarget.747 · Cited by 62
Targeting Oncogenic BRAF in Human Cancer
Pratilas, C. A., Xing, F., & Solit, D. B. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2011_162 · Cited by 63
Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Flanigan, S. A., Pitts, T. M., Newton, T. P., Kulikowski, G. N., Tan, A. C., McManus, M. C., Spreafico, A., Kachaeva, M. I., Selby, H. M., Tentler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0145 · Cited by 58
Current status and future direction in the management of malignant melanoma
Gladfelter, P., Darwish, N. H. E., & Mousa, S. A. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000379 · Cited by 55
Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17
Van Schaeybroeck, S., Kyula, J. N., Fenton, A., Fenning, C. S., Sasazuki, T., Shirasawa, S., Longley, D. B., & Johnston, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0714 · Cited by 51
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 67
The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
Wada, M., Horinaka, M., Yamazaki, T., Katoh, N., & Sakai, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113217 · Cited by 50
CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity
James, J., Ruggeri, B. R., Armstrong, R. C., Rowbottom, M. W., Jones‐Bolin, S., Gunawardane, R. N., Dobrzański, P., Gardner, M. F., Zhao, H. Q., Cramer, M. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0645 · Cited by 50
Role of B-RafV600E in differentiated thyroid cancer and preclinical validation of compounds against B-RafV600E
Nucera, C., Goldfarb, M. R., Hodin, R. A., & Parangi, S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.01.003 · Cited by 51
MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells
Miniotis, M. F., Arunan, V., Eykyn, T. R., Marais, R., Workman, P., Leach, M. O., & Beloueche‐Babari, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1969 · Cited by 49
Systems Pharmacology
Boran, A. D. W., & Iyengar, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20191 · Cited by 51
Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer
Wang, C., Wang, H., Zheng, C., Liu, Z., Gao, X., Xu, F., Niu, Y., Zhang, L., & Xu, P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113386 · Cited by 49
Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma
Wu, S., & Singh, R. K. (2011) · Current Molecular Medicine · doi:10.2174/156652411800615153 · Cited by 47
Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models
Morelli, M. P., Tentler, J. J., Kulikowski, G. N., Tan, A. C., Bradshaw‐Pierce, E. L., Pitts, T. M., Brown, A. M., Nallapareddy, S., Arcaroli, J. J., Serkova, N. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1507 · Cited by 46
The Biology and Clinical Development of MEK Inhibitors for Cancer
Luke, J. J., Ott, P. A., & Shapiro, G. I. (2014) · Drugs · doi:10.1007/s40265-014-0315-4 · Cited by 42
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies
Ricciardi, M. R., Scerpa, M. C., Bergamo, P., Ciuffreda, L., Petrucci, M. T., Chiaretti, S., Tavolaro, S., Mascolo, M. G., Abrams, S. L., Steelman, L. S., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0886-z · Cited by 43
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
Stones, C. J., Kim, J. E., Joseph, W. R., Leung, E. Y., Marshall, E. S., Finlay, G. J., Shelling, A. N., & Baguley, B. C. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00066 · Cited by 43
Specifically targeting ERK1 or ERK2 kills Melanoma cells
Qin, J., Xin, H., & Nickoloff, B. J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-15 · Cited by 44
mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells
Komatsu, N., Fujita, Y., Matsuda, M., & Aoki, K. (2015) · Oncogene · doi:10.1038/onc.2015.16 · Cited by 43
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
Yuan, X., Tang, Z., Du, R., Yao, Z., Cheung, S., Zhang, X., Wei, J., Zhao, Y., Du, Y., Liu, Y., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12698 · Cited by 40
Self-citation
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
Curatolo, A. D., Conciatori, F., Incani, U. C., Bazzichetto, C., Falcone, I., Corbo, V., D’Agosto, S. L., Eramo, A., Sette, G., Sperduti, I., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0820-5 · Cited by 36
Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy
El-Hachem, N., Gendoo, D. M. A., Ghoraie, L. S., Safikhani, Z., Smirnov, P., Chung, C., Deng, K., Fang, A., Birkwood, E., Ho, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0096 · Cited by 36
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 33
Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer
Liu, S., Zou, Q., Chen, J., Yao, X., Guan, P., Liang, W., Deng, P., Lai, X., Yin, J., Chen, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145035 · Cited by 33
Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells
Nishioka, C., Ikezoe, T., Yang, J., & Yokoyama, A. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0372-4 · Cited by 34
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Munck, J. M., Berdini, V., Bevan, L., Brothwood, J. L., Castro, J., Courtin, A., East, C., Ferraldeschi, R., Heightman, T. D., Hindley, C. J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0909 · Cited by 33
Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems
Nagaria, T. S., Shi, C., Leduc, C., Hoskin, V., Sikdar, S., Sangrar, W., & Greer, P. A. (2017) · Oncotarget · doi:10.18632/oncotarget.20534 · Cited by 32
The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF–MEK1/2–ERK1/2 Pathway
Bilal, F., Arenas, E. J., Pedersen, K., Martínez-Sabadell, A., Nabet, B., Guruceaga, E., Vicent, S., Tabernero, J. M., Macarulla, T. M., & Arribas, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4263 · Cited by 32
Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy
Daouti, S., Wang, H., Li, W., Higgins, B., Kolinsky, K. D., Packman, K. E., Specian, A., Kong, N., Huby, N. J. S., Yang, W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2627 · Cited by 32
Modelling signalling networks from perturbation data
Dorel, M., Klinger, B., Groß, T., Sieber, A., Prahallad, A., Bosdriesz, E., Wessels, L. F. A., & Blüthgen, N. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty473 · Cited by 31
Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1
Nishioka, C., Ikezoe, T., Yang, J., & Yokoyama, A. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0483-y · Cited by 30
Robustness of signal transduction pathways
Blüthgen, N., & Legewie, S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1162-7 · Cited by 31
Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors
Honda, K., Yamamoto, N., Nokihara, H., Tamura, Y., Asahina, H., Yamada, Y., Suzuki, S., Yamazaki, N., Ogita, Y., & Tamura, T. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2228-4 · Cited by 29
Design, biological evaluation and 3D QSAR studies of novel dioxin-containing triaryl pyrazoline derivatives as potential B-Raf inhibitors
Yang, Y., Yang, B., Zou, Y., Li, G., & Zhu, H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.012 · Cited by 29
Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2
Kidger, A. M., Munck, J. M., Saini, H. K., Balmanno, K., Minihane, E., Courtin, A., Graham, B. L., O’Reilly, M., Odle, R., & Cook, S. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0505 · Cited by 30
Distinct Genetic Alterations in the Mitogen-Activated Protein Kinase Pathway Dictate Sensitivity of Thyroid Cancer Cells to Mitogen-Activated Protein Kinase Kinase 1/2 Inhibition
Schweppe, R. E., Kerege, A. A., Sharma, V., Poczobutt, J. M., Gutierrez‐Hartmann, A., Grzywa, R. L., & Haugen, B. R. (2009) · Thyroid · doi:10.1089/thy.2008.0362 · Cited by 28
Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244
Ammoun, S., Ristic, N., Matthies, C., Hilton, D. A., & Hanemann, C. O. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.017 · Cited by 27
Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer
Sale, M. J., & Cook, S. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140129 · Cited by 25
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Flemington, V., Davies, E. J., Robinson, D. M., Sandin, L. C., Delpuech, O., Zhang, P., Hanson, L. L., Farrington, P. M., Bell, S., Falenta, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0002 · Cited by 26
Self-citation
Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy
Yu, C., Zhang, M., Song, J., Zheng, X., Xu, G., Bao, Y., Lan, J., Luo, D., Hu, J., Li, J. J., et al. (2020) · Molecular Biomedicine · doi:10.1186/s43556-020-00013-0 · Cited by 26
Self-citation
Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs
Fujita, Y., Komatsu, N., Matsuda, M., & Aoki, K. (2014) · FEBS Journal · doi:10.1111/febs.12852 · Cited by 25
Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL
Shukla, A., Rai, K., Shukla, V., Chaturvedi, N. K., Bociek, R. G., Pirruccello, S. J., Band, H., Lu, R., & Joshi, S. S. (2016) · Blood · doi:10.1182/blood-2015-09-669317 · Cited by 24
Inhibition of metadherin sensitizes breast cancer cells to AZD6244
Kong, X., Moran, M. S., Zhao, Y., & Yang, Q. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.1.18868 · Cited by 23
Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects
Smith, K. P., Gifford, K. M., Waitzman, J. S., & Rice, S. E. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24605 · Cited by 23
Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors
Duffy, A. G., & Kummar, S. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0125-x · Cited by 22
Vascular-targeted agents for the treatment of angiosarcoma
Young, R., Woll, P. J., Staton, C. A., Reed, M., & Brown, N. J. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2345-0 · Cited by 22
Role of the MEK Inhibitor Trametinib in the Treatment of Metastatic Melanoma
King, J., & Nathan, P. (2014) · Future Oncology · doi:10.2217/fon.14.89 · Cited by 21
Challenges in developing targeted therapy for pancreatic adenocarcinoma
Mahalingam, D., & Giles, F. J. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.11.1389 · Cited by 20
MEK inhibitors beyond monotherapy: current and future development.
Templeton, I. E., & Musib, L. (2015) · Current opinion in pharmacology (Print) · doi:10.1016/j.coph.2015.05.012 · Cited by 20
RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells
Mehta, P. P., Kung, P., Yamazaki, S., Walls, M., Shen, A., Nguyen, L., Gehring, M. R., Los, G., Smeal, T., & Yin, M.-J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.09.002 · Cited by 20
Retracted

Authors: Friday, B. B., Yu, C., Dy, G. K., Smith, P. D., Wang, L., Thibodeau, S. N., & Adjei, A. A.
Affiliations: Mayo Clinic (US)
Roswell Park Comprehensive Cancer Center (US)
AstraZeneca (United Kingdom) (GB)
ORCID: Dy, Grace K.
Smith, Paul D.
Wang, Liang
Thibodeau, Stephen N.
Adjei, Alex A.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2008-08-01
Volume: 68
Issue: 15
Pages: 6145-6153
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-08-1430
OpenAlex: W2124301770
Cited by: 146
References: 44
Citations by year: 2026: 1 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 5 · 2019: 3 · 2018: 8 · 2017: 8 · 2016: 7 · 2015: 10 · 2014: 12 · 2013: 12 · 2012: 12
FWCI: 6.30
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: Mayo Clinic
Array BioPharma
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: BRAF V600E mutation, selumetinib, MEK inhibitors, MAPK signaling, non-small cell lung cancer, G0/G1 cell cycle arrest, p21, p27, cyclin D1, drug sensitivity, KRAS mutation
MeSH terms: Base Sequence, Benzimidazoles, Humans, Mutation, Down-Regulation, Polymerase Chain Reaction, DNA Primers, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, raf Kinases, Proto-Oncogene Proteins B-raf, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase Inhibitor p27

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks